Dergiler / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 5

Increased plasma CgA levels associated with nonalcoholic fatty liver disease

Sayfa
404–7
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Increased plasma CgA levels were associated with NAFLD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Chromogranin A (CgA), a major soluble protein released by the neuroendocrine system, func- tions as a prohormone by giving rise to several biologically active peptides.
📊
Temel Bulgular & Veri:Materials and Methods: In total, 111 NAFLD patients and 120 healthy controls were enrolled in the trial.
💡
Sonuç & Katkı:Conclusion: Increased plasma CgA levels were associated with NAFLD.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Chromogranin A (CgA), a major soluble protein released by the neuroendocrine system, func- tions as a prohormone by giving rise to several biologically active peptides. Our study aimed to evaluate the rela- tionship between CgA levels and nonalcoholic fatty liver disease (NAFLD). Materials and Methods: In total, 111 NAFLD patients and 120 healthy controls were enrolled in the trial. The lev- els of plasma CgA were quantified by an available enzyme-linked immunosorbent assay kit. Pearsons correlation analysis was conducted to detect whether CgA levels correlated with oxidative stress, insulin resistance, and inflam- mation profile. A multiple stepwise regression model was used to explore independent determinants for plasma CgA levels. Multivariate logistic regression analysis was conducted to assess whether CgA levels were independent predictors of NAFLD. Results: The levels of plasma CgA between the case and control groups were significantly different (70.9±8.1 μg/L vs 47.6±11.3 μg/L). The levels of plasma CgA positively correlated with high-sensitivity C-reactive protein (hs-CRP; p=0.000), fasting blood glucose (FBG; p=0.025), homeostasis model assessment of insulin resistance index (HOMA- IR; p=0.012), and malondialdehyde (MDA; p=0.037) levels, but negatively associated with superoxide dismutase (SOD; p=0.041) levels. The multiple stepwise regression model indicated that hs-CRP, MDA, and HOMA-IR were independent determi- nants for plasma CgA levels. The logistic regression analysis showed that plasma levels of CgA were independent predictors of NAFLD. Conclusion: Increased plasma CgA levels were associated with NAFLD.

Abstract

Background/Aims: Chromogranin A (CgA), a major soluble protein released by the neuroendocrine system, func- tions as a prohormone by giving rise to several biologically active peptides. Our study aimed to evaluate the rela- tionship between CgA levels and nonalcoholic fatty liver disease (NAFLD). Materials and Methods: In total, 111 NAFLD patients and 120 healthy controls were enrolled in the trial. The lev- els of plasma CgA were quantified by an available enzyme-linked immunosorbent assay kit. Pearson s correlation analysis was conducted to detect whether CgA levels correlated with oxidative stress, insulin resistance, and inflam- mation profile. A multiple stepwise regression model was used to explore independent determinants for plasma CgA levels. Multivariate logistic regression analysis was conducted to assess whether CgA levels were independent predictors of NAFLD. Results: The levels of plasma CgA between the case and control groups were significantly different (70.9±8.1 μg/L vs 47.6±11.3 μg/L). The levels of plasma CgA positively correlated with high-sensitivity C-reactive protein (hs-CRP; p=0.000), fasting blood glucose (FBG; p=0.025), homeostasis model assessment of insulin resistance index (HOMA- IR; p=0.012), and malondialdehyde (MDA; p=0.037) levels, but negatively associated with superoxide dismutase (SOD; p=0.041) levels. The multiple stepwise regression model indicated that hs-CRP, MDA, and HOMA-IR were independent determi- nants for plasma CgA levels. The logistic regression analysis showed that plasma levels of CgA were independent predictors of NAFLD. Conclusion: Increased plasma CgA levels were associated with NAFLD.

🔖

Bu Makaleye Atıf Yap

WU, P., DENG, Y., SHUU, Y., TAN, S., LI, M., FANG, G. (2015). Increased plasma CgA levels associated with nonalcoholic fatty liver disease. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 5, 404–7. https://ajindex.com/articles/409415

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenter- ol Hepatol 2013; 10: 330-44
  2. Carazo A, Salmeron J. Obesity-related non-alcoholic fatty liver dis- ease (NAFLD): A multifactorial process. Rev Esp Enferm Dig 2014; 106: 501-4. Fasciotto BH, Denny JC, Greeley GH, Jr., Cohn DV. Processing of chromogranin A in the parathyroid: generation of parastatin-re- lated peptides. Peptides 2000; 21: 1389-401. D’Amico M A, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 2014; 3: R45-54. Sciola V, Massironi S, Conte D, et al. Plasma chromogranin a in pa- tients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 867-71. di Comite G, Marinosci A, Di Matteo P, et al. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheu- matoid arthritis. Ann N Y Acad Sci 2006; 1069: 428-37. Soell M, Feki A, Hannig M, Sano H, Pinget M, Selimovic D. Chro- mogranin A detection in saliva of type 2 diabetes patients. Bosn J Basic Med Sci 2010; 10: 2-8. Zhang D, Lavaux T, Sapin R, et al. Serum concentration of chromo- granin A at admission: an early biomarker of severity in critically ill patients. Ann Med 2009; 41: 38-44. Nadaoka I, Yasue M, Kitagawa Y, Koga Y. Oral administration of Cimicifuga racemosa extract attenuates psychological and physi- ological stress responses. Biomed Res 2012; 33: 145-52. Rabbi MF, Labis B, Metz-Boutigue MH, Bernstein CN, Ghia JE. Catestatin decreases macrophage function in two mouse models of experimental colitis. Biochem Pharmacol 2014; 89: 386-98. Gregorc V, Spreafico A, Floriani I, et al. Prognostic value of circulat- ing chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer 2007; 110: 845-53. Qiao XW, Qiu L, Chen YJ, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014; 14: 64. Maestroni S, Maestroni A, Ceglia S, et al. Effect of chromogranin A-derived vasostatin-1 on laser-induced choroidal neovascular- ization in the mouse. Acta Ophthalmol 2015; 93: e218-22. Hijioka M, Ito T, Igarashi H, et al. Serum chromogranin A is a use- ful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci 2014; 105: 1464-71. Valicherla GR, Hossain Z, Mahata SK, Gayen JR. Pancreastatin is an endoge